Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study | Zendy

Alex Z. Fu | Zendy; Stephen S. Johnston | Zendy; Ameen Ghannam | Zendy; Katherine Tsai | Zendy; Katherine Cappell | Zendy; Robert Fowler | Zendy; Ellen Riehle | Zendy; Ashley L. Cole | Zendy; Iftekhar Kalsekar | Zendy; John J. Sheehan | Zendy

Open Access

Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study

Author(s) -

Alex Z. Fu,

Stephen S. Johnston,

Ameen Ghannam,

Katherine Tsai,

Katherine Cappell,

Robert Fowler,

Ellen Riehle,

Ashley L. Cole,

Iftekhar Kalsekar,

John J. Sheehan

Publication year - 2016

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc15-0764

Subject(s) - saxagliptin , sitagliptin , medicine , hazard ratio , propensity score matching , dipeptidyl peptidase 4 inhibitor , observational study , vildagliptin , type 2 diabetes , diabetes mellitus , proportional hazards model , heart failure , confidence interval , endocrinology

To examine, among patients with type 2 diabetes, the association between hospitalization for heart failure (hHF) and treatment with dipeptidyl peptidase 4 inhibitors (DPP-4is) versus sulfonylureas (SUs), and treatment with saxagliptin versus sitagliptin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research